I hold the Alan Mackay-Sim Distinguished Chair of Cancer Cell Biology at Griffith University, Nathan, Brisbane, and I am a National Health and Medical Research Council (NHMRC) of Australia Senior Principal Research Fellow. I am a multi-disciplinary medicinal chemist/biochemist/pharmacologist whose career has spanned medicinal chemistry, drug design/development/commercialisation, cancer biology, and neurobiology. I have published 465 articles, reviews, patents, chapters etc., over my career with >91% as first, senior, or corresponding author (H-index: 101; >45,000 citations over entire career; Google Scholar 5/10/22; with >20,800 citations over the past 5 years and H-index of 62 past 5 years; Google Scholar 5/10/22). I was recently honoured by the international Otto Krayer Award in Pharmacology 2022 from the American Society of Pharmacology & Experimental Therapeutics (ASPET). I am Executive Editor of BBA-General Subjects and have served on the Ed. Boards of 49 journals, including: JBC, Antioxidants Redox Signaling, Biochem. J., Free Radic. Biol. Med., Pharmacol. Res., J. Clin. Pathology (Assoc. Ed.), Int. J. Biochem. Cell Biology, BBA-Mol. Cell. Res., Mol. Pharmacol., Pharmacol. Res., Cancers, etc. As a major translational research achievement, I developed the redox active anti-cancer and anti-metastatic drug, DpC, which overcomes P-glycoprotein-mediated resistance and up-regulates the metastasis suppressor, NDRG1. This has led to commercialisation of DpC and the international company, Oncochel Therapeutics LLC, USA and its Australian subsidiary, Oncochel Therapeutics Pty Ltd. Notably, DpC entered multi-centre Phase I clinical trials for advanced and resistant cancer. These anti-cancer drugs target the lysosome via the P-glycoprotein transporter.